Julian Robert Thorpe

Julian Robert Thorpe

Auto-generated profile, based on publicly available information

Julian Robert Thorpe

University of Sussex

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Neuron
Verified
Journal Article
Closed access
DSDavid W. Sanders
David W. Sanders
SKSarah K. Kaufman
Sarah K. Kaufman
SDSarah L. DeVos
Sarah L. DeVos
ASApurwa M. Sharma
Apurwa M. Sharma
HMHilda Mirbaha
Hilda Mirbaha
MDMarc I. Diamond
Marc I. Diamond

30 June 2000 in Biochemistry
Verified
Journal Article
Closed access
MPMaya J. Pandya
Maya J. Pandya
GSGillian M. Spooner
Gillian M. Spooner
MSMargaret Sunde
Margaret Sunde
JTJulian R. Thorpe
Julian R. Thorpe
Alison RodgerAlison Rodger
Alison Rodger
DWDerek N. Woolfson
Derek N. Woolfson

18 December 2013 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YAYoussra Al-Hilaly
Youssra Al-Hilaly
TWTom Williams
Tom Williams
MSMaris Stewart-Parker
Maris Stewart-Parker
LFLenzie Ford
Lenzie Ford
ESEldhose Skaria
Eldhose Skaria
LSLouise Serpell
Louise Serpell
Alzheimer’s disease (AD) is characterized by the deposition of insoluble amyloid plaques in the neuropil composed of highly stable, self-assembled Amyloid-beta (Aβ) fibrils. Copper has been implicated to play a role in Alzheimer’s disease. Dimers of Aβ have been isolated from AD brain and have been shown to be neurotoxic.

26 October 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
NCN. J. Cairns
N. J. Cairns
MGM. Grossman
M. Grossman
SAS. E. Arnold
S. E. Arnold
DBD. J. Burn
D. J. Burn
EJE. Jaros
E. Jaros
JTJ .Q. Trojanowski
J .Q. Trojanowski
Background: Recently described neuronal intermediate filament inclusion disease (NIFID) shows considerable clinical heterogeneity. Objective: To assess the spectrum of the clinical and neuropathological features in 10 NIFID cases. Methods: Retrospective chart and comprehensive neuropathological review of these NIFID cases was conducted. Results: The mean age at onset was 40.8 (range 23 to 56) years, mean disease duration was 4.5 (range 2.7 to 13) years, and mean age at death was 45.3 (range 28 to 61) years. The most common presenting symptoms were behavioral and personality changes in 7 of 10 cases and, less often, memory loss, cognitive impairment, language deficits, and motor weakness. Extrapyramidal features were present in 8 of 10 patients. Language impairment, perseveration, executive dysfunction, hyperreflexia, and primitive reflexes were frequent signs, whereas a minority had buccofacial apraxia, supranuclear ophthalmoplegia, upper motor neuron disease (MND), and limb dystonia. Frontotemporal and caudate atrophy were common. Histologic changes were extensive in many cortical areas, deep gray matter, cerebellum, and spinal cord. The hallmark lesions of NIFID were unique neuronal IF inclusions detected most robustly by antibodies to neurofilament triplet proteins and α-internexin. Conclusion: NIFID is a neuropathologically distinct, clinically heterogeneous variant of frontotemporal dementia (FTD) that may include parkinsonism or MND. Neuronal IF inclusions are the neuropathological signatures of NIFID that distinguish it from all other FTD variants including FTD with MND and FTD tauopathies.

1 November 2012 in Neuron
Verified
Journal Article
Open access
VMVincenzo Marra
Vincenzo Marra
JBJemima Burden
Jemima Burden
JTJulian R. Thorpe
Julian R. Thorpe
ISIkuko T. Smith
Ikuko T. Smith
SSSpencer L. Smith
Spencer L. Smith
KSKevin Staras
Kevin Staras
At small central synapses, efficient turnover of vesicles is crucial for stimulus-driven transmission, but how the structure of this recycling pool relates to its functional role remains unclear. Here we characterize the organizational principles of functional vesicles at native hippocampal synapses with nanoscale resolution using fluorescent dye labeling and electron microscopy. We show that the recycling pool broadly scales with the magnitude of the total vesicle pool, but its average size is small (∼45 vesicles), highly variable, and regulated by CDK5/calcineurin activity. Spatial analysis demonstrates that recycling vesicles are preferentially arranged near the active zone and this segregation is abolished by actin stabilization, slowing the rate of activity-driven exocytosis. Our approach reveals a similarly biased recycling pool distribution at synapses in visual cortex activated by sensory stimulation in vivo. We suggest that in small native central synapses, efficient release of a limited pool of vesicles relies on their favored spatial positioning within the terminal.

1 September 2011 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
AAAbraham Acevedo-Arozena
Abraham Acevedo-Arozena
BKBernadett Kalmar
Bernadett Kalmar
SEShafa Essa
Shafa Essa
TRThomas Ricketts
Thomas Ricketts
PJPeter Joyce
Peter Joyce
EFElizabeth M. C. Fisher
Elizabeth M. C. Fisher
SUMMARY Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that results in the death of motor neurons in the brain and spinal cord. The disorder generally strikes in mid-life, relentlessly leading to paralysis and death, typically 3–5 years after diagnosis. No effective treatments are available. Up to 10% of ALS is familial, usually autosomal dominant. Several causative genes are known and, of these, mutant superoxide dismutase 1 (SOD1) is by far the most frequently found, accounting for up to 20% of familial ALS. A range of human mutant SOD1 transgenic mouse strains has been produced, and these largely successfully model the human disease. Of these, the most widely used is the SOD1 mouse, which expresses a human SOD1 transgene with a causative G93A mutation. This mouse model is excellent for many purposes but carries up to 25 copies of the transgene and produces a great excess of SOD1 protein, which might affect our interpretation of disease processes. A variant of this strain carries a deletion of the transgene array such that the copy number is dropped to eight to ten mutant SOD1 genes. This ‘deleted’ ‘low-copy’ mouse undergoes a slower course of disease, over many months. Here we have carried out a comprehensive analysis of phenotype, including nerve and muscle physiology and histology, to add to our knowledge of this ‘deleted’ strain and give baseline data for future studies. We find differences in phenotype that arise from genetic background and sex, and we quantify the loss of nerve and muscle function over time. The slowly progressive pathology observed in this mouse strain could provide us with a more appropriate model for studying early-stage pathological processes in ALS and aid the development of therapies for early-stage treatments.